NASDAQ:BIVI BioVie Q3 2025 Earnings Report $2.03 0.00 (0.00%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast BioVie EPS ResultsActual EPS-$1.50Consensus EPS -$3.20Beat/MissBeat by +$1.70One Year Ago EPSN/ABioVie Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABioVie Announcement DetailsQuarterQ3 2025Date5/12/2025TimeBefore Market OpensConference Call DateSunday, May 11, 2025Conference Call Time6:00PM ETUpcoming EarningsBioVie's Q1 2027 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) BioVie Earnings HeadlinesBioVie Inc. (NASDAQ:BIVI) Short Interest Up 56.7% in AugustSeptember 1 at 1:42 AM | americanbankingnews.comBioVie completes final patient visit in Phase 2 Long COVID trialAugust 31 at 9:24 AM | proactiveinvestors.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.September 3 at 1:00 AM | Chaikin Analytics (Ad)BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVIDAugust 31 at 8:00 AM | globenewswire.comBioVie Inc. (BIVI) Discusses Bezisterim Mechanism of Action and SUNRISE-PD Phase II Trial Design TranscriptAugust 12, 2026 | seekingalpha.comWhy BioVie (BIVI) Stock Is Up TodayAugust 12, 2026 | quiverquant.comQSee More BioVie Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BioVie? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioVie and other key companies, straight to your email. Email Address About BioVieBioVie (NASDAQ:BIVI) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for chronic liver diseases and associated neurological complications. The company’s research and development efforts center on candidates designed to address serious unmet medical needs in hepatic encephalopathy and other liver‐related disorders. BioVie advances its pipeline through controlled clinical trials and regulatory interactions in North America. The company’s lead product candidate, BIV201, is undergoing Phase 2 clinical evaluation for the treatment of hepatic encephalopathy, a life‐threatening condition marked by elevated neurotoxins in patients with advanced liver disease. BIV201 is being assessed for its potential to reduce ammonia levels and improve cognitive function, with data from early studies indicating a favorable safety profile and signs of clinical benefit. In addition to its lead program, BioVie maintains exploratory efforts targeting other chronic liver indications, including primary biliary cholangitis and alcohol‐associated liver disease. These preclinical and early‐stage candidates leverage the company’s expertise in small‐molecule modulation of metabolic and inflammatory pathways, with the goal of expanding treatment options for patients who currently have limited therapeutic choices. Headquartered in Emeryville, California, BioVie was founded with the mission of transforming the management of liver diseases through innovative drug development. The company operates in collaboration with leading academic institutions and clinical research organizations across the United States and Canada. Guided by an experienced executive team with backgrounds in biotechnology and pharmaceutical development, BioVie is committed to advancing its portfolio toward late‐stage clinical trials and eventual regulatory approval.View BioVie ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AeroVironment’s $465 Million Army Laser Win Expands Its Counter-Drone OpportunityThe Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth StoryPalo Alto Networks Is Expensive—But Its Growth Is AcceleratingMongoDB’s Spending Fears Collide With a Much Stronger Growth StoryGitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse TestWith the RSI at a Record Low, Is It Time to Go Bargain Hunting on Burlington?Enova’s Earnings Surge Meets a Valuation Test Upcoming Earnings Oracle (9/8/2026)Adobe (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
